Repurposing Generic (ReGen) Drugs Evidence Package Challenge supports individuals, teams, and entities developing evidence for new generic drug uses in high-cost conditions to advance access to affordable treatments.
Registration is now open until January 15, 2027, at 5 p.m. ET, replacing the notice that registration would open November 2, 2026. A direct registration link has also been added.
Funder: NIH Challenges
Due Dates: January 15, 2027, 5 p.m. ET (Registration) | March 26, 2027 (Evidence package) | June 3, 2027 (Review completed) | July 2, 2027 (Winners announced)
Funding Amounts: Up to 40 prizes of $100,000 each; total prize purse up to $4 million
Summary: Supports evidence packages identifying promising new uses of generic drugs for high-cost conditions.
Key Information: Clinical efficacy evidence beyond case reports or a single institution’s experience is required for judging.
The National Center for Advancing Translational Sciences (NCATS) at NIH runs this prize challenge to identify evidence-based generic drug–disease pairs for high-cost conditions. It is the first step in the broader ReGen Drugs program, which aims to identify repurposing opportunities, build supporting evidence, and expand access to affordable treatments.
Evidence packages should thoroughly review safety and effectiveness for a proposed new use. The challenge prioritizes opportunities worth testing in clinical trials and those with substantial existing evidence that could support FDA labeling or compendia updates. Highest priorities include uses in a completely different disease class, uses not commonly prescribed off label, and new indications identified through real-world evidence but not currently prescribed. Submissions may inform future evidence-generation opportunities supporting treatment coverage and clinical adoption.